151 related articles for article (PubMed ID: 33659039)
1. Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Takebe N; Coyne GO; Kummar S; Collins J; Reid JM; Piekarz R; Moore N; Juwara L; Johnson BC; Bishop R; Lin FI; Mena E; Choyke PL; Lindenberg ML; Rubinstein LV; Bonilla CM; Goetz MP; Ames MM; McGovern RM; Streicher H; Covey JM; Doroshow JH; Chen AP
Oncotarget; 2021 Feb; 12(4):268-277. PubMed ID: 33659039
[TBL] [Abstract][Full Text] [Related]
2. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
3. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ; Ralya AT; Larson TR; McGovern RM; Buhrow SA; Covey JM; Adjei AA; Takebe N; Ames MM; Goetz MP; Reid JM
J Clin Pharmacol; 2022 Sep; 62(9):1121-1131. PubMed ID: 35358345
[TBL] [Abstract][Full Text] [Related]
5. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM; Helland T; Klima F; Koolen SLW; van Schaik RHN; Mathijssen RHJ; Neven P; Swen JJ; Guchelaar HJ; Dalenc F; White-Koning M; Michelet R; Mikus G; Schroth W; Mürdter T; Brauch H; Schwab M; Søiland H; Mellgren G; Thomas F; Kloft C; Hertz DL;
Clin Pharmacol Ther; 2024 Mar; ():. PubMed ID: 38494911
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
7. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
[No Abstract] [Full Text] [Related]
9.
Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
[TBL] [Abstract][Full Text] [Related]
10. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trial:
Khalaj Z; Baratieh Z; Nikpour P; Schwab M; Schaeffeler E; Mokarian F; Khanahmad H; Salehi R; Mürdter TE; Salehi M
Front Pharmacol; 2019; 10():530. PubMed ID: 31178724
[No Abstract] [Full Text] [Related]
13.
Tamura K; Imamura CK; Takano T; Saji S; Yamanaka T; Yonemori K; Takahashi M; Tsurutani J; Nishimura R; Sato K; Kitani A; Ueno NT; Mushiroda T; Kubo M; Fujiwara Y; Tanigawara Y
J Clin Oncol; 2020 Feb; 38(6):558-566. PubMed ID: 31821071
[TBL] [Abstract][Full Text] [Related]
14. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.
Hussaarts KGAM; Hurkmans DP; Oomen-de Hoop E; van Harten LJ; Berghuis S; van Alphen RJ; Spierings LEA; van Rossum-Schornagel QC; Vastbinder MB; van Schaik RHN; van Gelder T; Jager A; van Leeuwen RWF; Mathijssen RHJ
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909366
[TBL] [Abstract][Full Text] [Related]
15. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.
Jager NG; Rosing H; Schellens JH; Beijnen JH; Linn SC
Breast Cancer Res Treat; 2014 Jul; 146(1):137-44. PubMed ID: 24859000
[TBL] [Abstract][Full Text] [Related]
16. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.
Lee O; Bazzi LA; Xu Y; Pearson E; Wang M; Hosseini O; Akasha AM; Choi JN; Karlan S; Pilewskie M; Kocherginsky M; Benante K; Helland T; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Khan SA
Biomed Pharmacother; 2024 Feb; 171():116105. PubMed ID: 38171245
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
18. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
[TBL] [Abstract][Full Text] [Related]
20. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
